Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
Jonathan Corren,David J Jackson,Thomas B Casale,Larry Borish,Klaus F Rabe,William W Busse,Jorge F Maspero,Daniel J Jackson,Nadia Daizadeh,Arman Altincatal,Amr Radwan,Angela Khodzhayev,Michel Djandji,Juby A Jacob-Nara,Paul J Rowe,Yamo Deniz
DOI: https://doi.org/10.2147/JAA.S385645
2023-03-08
Journal of Asthma and Allergy
Abstract:Jonathan Corren, 1 David J Jackson, 2, 3 Thomas B Casale, 4 Larry Borish, 5, 6 Klaus F Rabe, 7, 8 William W Busse, 9 Jorge F Maspero, 10 Daniel J Jackson, 11 Nadia Daizadeh, 12 Arman Altincatal, 12 Amr Radwan, 13 Angela Khodzhayev, 13 Michel Djandji, 12 Juby A Jacob-Nara, 12, 14 Paul J Rowe, 14 Yamo Deniz 13 1 David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2 King's College London, London, UK; 3 Guy's and St Thomas' NHS Foundation Trust, London, UK; 4 Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 5 Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA; 6 Carter Immunology Center, University of Virginia Health System, Charlottesville, VA, USA; 7 LungenClinic Grosshansdorf (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany; 8 Christian-Albrechts University (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany; 9 UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 10 Fundación CIDEA, Buenos Aires, Argentina; 11 University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 12 Sanofi, Cambridge, MA, USA; 13 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 14 Sanofi, Bridgewater, NJ, USA Correspondence: Jonathan Corren, David Geffen School of Medicine at UCLA, 10780 Santa Monica Blvd., Suite 280, Los Angeles, CA, 90025, USA, Email Purpose: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), dupilumab vs placebo significantly reduced asthma exacerbation rates (AER) and improved pre-bronchodilator forced expiratory volume in 1 second (FEV 1 ) in patients with uncontrolled, moderate-to-severe asthma, with greater effects in patients with elevated T2 biomarkers (≥ 150 eosinophils/μL or fractional exhaled nitric oxide [FeNO] ≥ 25 parts per billion). Overall safety was consistent with the known dupilumab safety profile. This post hoc analysis assessed dupilumab efficacy in QUEST patients with T2 asthma with evidence of an allergic phenotype (baseline serum IgE ≥ 30 IU/mL and aeroallergen-specific IgE ≥ 0.35 IU/mL) by number of aeroallergen sensitizations: 1, 2, 3, or ≥ 4. Non-sensitized patients (serum total IgE < 30 IU/mL without evidence of allergic phenotype) were also assessed. Patients and Methods: Endpoints were annualized AER, change from baseline in pre-bronchodilator FEV 1 and asthma control (5-item Asthma Control Questionnaire [ACQ-5]), and FeNO and serum total IgE levels over the 52-week treatment period. Results: In all subgroups by number of allergens sensitized, dupilumab vs placebo reduced AER by 35– 67% and improved both pre-bronchodilator FEV 1 at Week 12 (least squares mean differences: 0.10– 0.26 L across subgroups) and ACQ-5 score at Week 52 (– 0.26 to – 0.43). Dupilumab significantly reduced FeNO and total IgE levels at Week 52 compared with placebo. Similar results were observed in non-sensitized patients. Conclusion: Dupilumab improved clinical outcomes and reduced biomarker levels in patients with uncontrolled, moderate-to-severe T2 asthma irrespective of allergen sensitization status or number. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02414854. Keywords: dupilumab, allergic asthma, type 2 asthma, perennial aeroallergen Patients with type 2 inflammation represent a large proportion of the overall population of patients with asthma. Many of those with type 2 asthma also have evidence of an allergic phenotype, which is characterized by an increased expression of specific IgE to 1 or more aeroallergens. 1,2 Re-exposure to allergens and their binding to IgE results in the release of inflammatory mediators that attract T helper type 2 cells. These, in turn, secrete cytokines, including interleukin (IL)-4, IL-13, and IL-5, all of which are thought to contribute to the airway inflammation associated with allergic asthma. 2 These cytokines are also key drivers in type 2 inflammatory pathways and, in recent years, a number of biologics have been developed to target them and inhibit their signaling. 3 One of these, dup -Abstract Truncated-
immunology,allergy,respiratory system